31 May 2024
Annual report highlights progress in science, medicines and health in 2023
The European Medicines Agency’s 2023 annual report highlights its contributions to public and animal health in the EU, with a focus on cancer medicines, data-driven medicine regulation, and transparency. The agency recommended 77 medicines for human use and 14 for veterinary use, including the first CRISPR/Cas9 gene-editing therapy. EMA also launched the "Cancer Medicines Pathfinder" initiative to improve medicine evaluation and patient care. The report underscores EMA’s commitment to leveraging data for innovation and maintaining transparency in its communications.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting